Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
75.27
+0.51 (0.68%)
At close: May 1, 2026, 4:00 PM EDT
75.30
+0.03 (0.04%)
After-hours: May 1, 2026, 7:45 PM EDT
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $246.09M in the quarter ending March 31, 2026, with 86.98% growth. This brings the company's revenue in the last twelve months to $1.06B, up 47.53% year-over-year. In the year 2025, Ionis Pharmaceuticals had annual revenue of $943.71M with 33.83% growth.
Revenue (ttm)
$1.06B
Revenue Growth
+47.53%
P/S Ratio
11.76
Revenue / Employee
$754,772
Employees
1,402
Market Cap
12.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 943.71M | 238.57M | 33.83% |
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | 1.12B | 522.93M | 87.20% |
| Dec 31, 2018 | 599.67M | 85.50M | 16.63% |
| Dec 31, 2017 | 514.18M | 141.40M | 37.93% |
| Dec 31, 2016 | 372.78M | 89.07M | 31.40% |
| Dec 31, 2015 | 283.70M | 69.54M | 32.47% |
| Dec 31, 2014 | 214.16M | 66.88M | 45.41% |
| Dec 31, 2013 | 147.29M | 45.24M | 44.33% |
| Dec 31, 2012 | 102.05M | 2.96M | 2.99% |
| Dec 31, 2011 | 99.09M | -9.39M | -8.65% |
| Dec 31, 2010 | 108.47M | -13.13M | -10.80% |
| Dec 31, 2009 | 121.60M | 14.41M | 13.44% |
| Dec 31, 2008 | 107.19M | 48.85M | 83.72% |
| Dec 31, 2007 | 58.34M | 43.49M | 292.65% |
| Dec 31, 2006 | 14.86M | -13.48M | -47.57% |
| Dec 31, 2005 | 28.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Ascendis Pharma | 845.52M |
| Axsome Therapeutics | 638.50M |
IONS News
- 2 days ago - Ionis to present at upcoming investor conferences - Business Wire
- 4 days ago - Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 4 days ago - Ionis reports first quarter 2026 financial results and highlights progress on key programs - Business Wire
- 5 days ago - Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B - Business Wire
- 12 days ago - Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting - Business Wire
- 18 days ago - Ionis to hold first quarter 2026 financial results webcast - Business Wire
- 4 weeks ago - FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - GlobeNewsWire
- 5 weeks ago - Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market - Benzinga